@article{oai:hama-med.repo.nii.ac.jp:00004039,
 author = {Naoi, Hyogo and Suzuki, Yuzo and Mori, Kazutaka and Aono, Yuya and Kono, Masato and Hasegawa, Hirotsugu and Yokomura, Koshi and Inoue, Yusuke and Hozumi, Hironao and Karayama, Masato and Furuhashi, Kazuki and Enomoto, Noriyuki and Fujisawa, Tomoyuki and Nakamura, Yutaro and Inui, Naoki and Nakamura, Hidenori and Suda, Takafumi},
 issue = {7},
 journal = {Thorax},
 month = {},
 note = {Patients with idiopathic pulmonary fibrosis (IPF) are at a high risk for lung cancer (LC). Antifibrotic therapy slows disease progression and possibly prolongs survival. However, whether antifibrotic therapy affects LC-development in IPF patients remains unknown. This multi-centre retrospective study evaluated 345 IPF patients. The incidence and prevalence of LC were significantly lower in IPF patients receiving antifibrotic therapy than those not. Subsequently, LC-related mortality was significantly lower in IPF patients receiving antifibrotic therapy. These results suggest that antifibrotic therapy was possibly associated with a reduced risk of LC-development in IPF patients, which may be partly associated with its survival benefit.},
 pages = {727--730},
 title = {Impact of antifibrotic therapy on lung cancer development in idiopathic pulmonary fibrosis},
 volume = {77},
 year = {2022}
}